- Home
- RAPP vs CLOV Comparison
RAPP vs CLOV Comparison
Compare RAPP & CLOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAPP | CLOV |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RAPP | CLOV |
|---|---|---|
| Price | $41.47 | $4.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $48.50 | $2.90 |
| AVG Volume (30 Days) | 292.3K | ★ 3.8M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.34 | ★ 38.03 |
| EPS | N/A | ★ 0.10 |
| Revenue | N/A | ★ $1,924,308,000.00 |
| Revenue This Year | N/A | $52.59 |
| Revenue Next Year | N/A | $15.37 |
| P/E Ratio | ★ N/A | $45.40 |
| Revenue Growth | N/A | ★ 40.34 |
| 52 Week Low | $23.75 | $1.58 |
| 52 Week High | $52.93 | $5.59 |
Technical Indicators
Market Signals| Indicator | RAPP | CLOV |
|---|---|---|
| Relative Strength Index (RSI) | 27.77 | 54.28 |
| Support Level | $33.54 | $4.10 |
| Resistance Level | $40.61 | $5.19 |
| Average True Range (ATR) | 2.15 | 0.22 |
| MACD | -0.96 | 0.02 |
| Stochastic Oscillator | 0.82 | 46.01 |
Price Performance
Historical ComparisonAbout RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
About CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.